BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 27340238)

  • 1. Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer.
    Hutton JE; Wang X; Zimmerman LJ; Slebos RJ; Trenary IA; Young JD; Li M; Liebler DC
    Mol Cell Proteomics; 2016 Sep; 15(9):2924-38. PubMed ID: 27340238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
    J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
    J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.
    Fritsche-Guenther R; Zasada C; Mastrobuoni G; Royla N; Rainer R; Roßner F; Pietzke M; Klipp E; Sers C; Kempa S
    Sci Rep; 2018 Jun; 8(1):9204. PubMed ID: 29907857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells.
    Yun J; Rago C; Cheong I; Pagliarini R; Angenendt P; Rajagopalan H; Schmidt K; Willson JK; Markowitz S; Zhou S; Diaz LA; Velculescu VE; Lengauer C; Kinzler KW; Vogelstein B; Papadopoulos N
    Science; 2009 Sep; 325(5947):1555-9. PubMed ID: 19661383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF provides proliferation and survival signals in MSI colorectal carcinoma cells displaying BRAF(V600E) but not KRAS mutations.
    Preto A; Figueiredo J; Velho S; Ribeiro AS; Soares P; Oliveira C; Seruca R
    J Pathol; 2008 Feb; 214(3):320-7. PubMed ID: 18098337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines.
    Khan S; Cameron S; Blaschke M; Moriconi F; Naz N; Amanzada A; Ramadori G; Malik IA
    World J Gastroenterol; 2014 Mar; 20(11):2979-94. PubMed ID: 24659889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mutations of KRAS and BRAF in Chinese patients with colorectal carcinoma: analyses of 966 cases].
    Gao J; Sun ZW; Li YY; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):579-83. PubMed ID: 23157823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
    Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
    J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS, BRAF and PIK3CA mutations in human colorectal cancer: relationship with metastatic colorectal cancer.
    Li HT; Lu YY; An YX; Wang X; Zhao QC
    Oncol Rep; 2011 Jun; 25(6):1691-7. PubMed ID: 21424126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH.
    Yun J; Mullarky E; Lu C; Bosch KN; Kavalier A; Rivera K; Roper J; Chio II; Giannopoulou EG; Rago C; Muley A; Asara JM; Paik J; Elemento O; Chen Z; Pappin DJ; Dow LE; Papadopoulos N; Gross SS; Cantley LC
    Science; 2015 Dec; 350(6266):1391-6. PubMed ID: 26541605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncogenic mutation in RAS-RAF axis leads to increased expression of GREB1, resulting in tumor proliferation in colorectal cancer.
    Kochi M; Hinoi T; Niitsu H; Miguchi M; Saito Y; Sada H; Sentani K; Sakamoto N; Oue N; Tashiro H; Sotomaru Y; Yasui W; Ohdan H
    Cancer Sci; 2020 Oct; 111(10):3540-3549. PubMed ID: 32629543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS and BRAF mutations in Serbian patients with colorectal cancer.
    Jakovljevic K; Malisic E; Cavic M; Krivokuca A; Dobricic J; Jankovic R
    J BUON; 2012; 17(3):575-80. PubMed ID: 23033302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
    Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
    Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between 18F-fluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer.
    Kawada K; Nakamoto Y; Kawada M; Hida K; Matsumoto T; Murakami T; Hasegawa S; Togashi K; Sakai Y
    Clin Cancer Res; 2012 Mar; 18(6):1696-703. PubMed ID: 22282467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [BRAF gene mutation in wild-type KRAS patients with colorectal cancers].
    Roa I; Game A; Bizama C; Schalper K
    Rev Med Chil; 2014 Jan; 142(1):55-60. PubMed ID: 24861115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal neuroendocrine carcinomas and adenocarcinomas share oncogenic pathways. A clinico-pathologic study of 12 cases.
    Karkouche R; Bachet JB; Sandrini J; Mitry E; Penna C; Côté JF; Blons H; Penault-Llorca F; Rougier P; Saint André JP; Emile JF
    Eur J Gastroenterol Hepatol; 2012 Dec; 24(12):1430-7. PubMed ID: 23114745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proprotein convertase furin is a pro-oncogenic driver in KRAS and BRAF driven colorectal cancer.
    He Z; Thorrez L; Siegfried G; Meulemans S; Evrard S; Tejpar S; Khatib AM; Creemers JWM
    Oncogene; 2020 Apr; 39(17):3571-3587. PubMed ID: 32139876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.